NCT02089659View on ClinicalTrials.gov

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

May 12, 2014

Study Completion Date

May 12, 2014

Conditions
HIV-1 Infection
Interventions
DRUG

Doravirine

Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02089659 - A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019) | Biotech Hunter | Biotech Hunter